S090.F Sutro Biopharma Inc.

Healthcare Biotechnology Frankfurt Exchange
11.50 EUR
Close of Nov 12, 2026
6.53 36.00
Market cap
EUR 191M
P/E
-
P/B
2.13x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is S090.F undervalued?

Graham number

The Graham number of Sutro Biopharma Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Sutro Biopharma Inc. fundamental analysis

No fundamental analysis for Sutro Biopharma Inc. yet.

Sutro Biopharma Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Sutro Biopharma Inc.

Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including non-small cell lung cancer, head and neck squamous cell carci…

Full company profile